Barclays reissued their underweight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report released on Monday.

A number of other analysts also recently weighed in on the company. Citigroup increased their price objective on Hikma Pharmaceuticals from GBX 1,675 ($21.82) to GBX 2,100 ($27.35) and gave the company a buy rating in a report on Monday, August 20th. Peel Hunt restated a hold rating on shares of Hikma Pharmaceuticals in a report on Thursday, May 31st. JPMorgan Chase & Co. restated a neutral rating and issued a GBX 1,050 ($13.68) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Finally, Numis Securities restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of GBX 1,330.22 ($17.33).

LON HIK opened at GBX 1,879 ($24.48) on Monday. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($10.61) and a twelve month high of GBX 2,346 ($30.56).

The company also recently declared a dividend, which was paid on Friday, September 21st. Shareholders of record on Thursday, August 23rd were given a dividend of $0.12 per share. The ex-dividend date of this dividend was Thursday, August 23rd. This represents a yield of 0.53%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

See Also: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.